Zealand Pharma A/s buy stratec
Start price
12.06.18
/
50%
€12.84
Target price
12.12.18
€21.41
Performance (%)
-11.68%
End price
12.12.18
€11.34
Summary
This prediction ended on 12.12.18 with a price of €11.34. The price of Zealand Pharma A/s has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -11.68%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Zealand Pharma A/s | -3.388% | -3.388% | 282.526% | 354.510% |
| iShares Core DAX® | -3.935% | -2.628% | 10.013% | 11.951% |
| iShares Nasdaq 100 | -3.608% | -9.283% | 20.668% | 35.711% |
| iShares Nikkei 225® | -4.513% | -6.951% | 5.241% | 2.602% |
| iShares S&P 500 | -2.607% | -4.402% | 20.177% | 37.820% |
Comments by stratec for this prediction
In the thread Zealand Pharma A/s diskutieren
stratec stimmt der Outperform-Einschätzung der institutionellen Analysten zu
stratec stimmt am 12.06.2018 der Outperform-Einschätzung der institutionellen Analysten mit dem Kursziel 21.41€ zu.
ZEAL announced updated top-line findings from its ongoing phase 3 study evaluating dasiglucagon compared with glucagon. The study met its primary and key secondary endpoints, which included immunogenicity and safety/tolerability of this glucagon mimetic. This builds on phase 2 findings showing long-lasting recovery of plasma glucose, suggesting efficacy for this agent.
If approved, this will be the first glucagon analog to be available for patients at risk for developing hypoglycemia, mainly those with Type 1 diabetes. The value proposition here is that the analog can be manufactured into a liquid formulation that is ready-made for injection by patients who are currently undergoing a hypoglycemic attack. Current preparations of glucagon have to be solubilized first, leaving room for error if patients are to deliver the drug themselves. So the fact that this analog is passing the safety and efficacy hurdles is very promising!
(Laufzeit überschritten)
Stopped prediction by stratec for Zealand Pharma A/s
Zealand Pharma A/s
Start price
Target price
Perf. (%)
€24.02
22.10.19
22.10.19
€35.00
04.11.21
04.11.21
13.91%
05.11.21
05.11.21
